Invasive candida infections in critically ill patients;Candidoses invasives en reanimation

Schweizerische Medizinische Wochenschrift

Volumn 130, Issue 42, 2000, Pages 1525-1537

  Eggimann, Ph ^a   Pittet, D ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Amphotericin B; Candida spp; Candidaemia; Candidiasis; Epidemiology; Nosocomial infections; Prophylaxis; Risk factors; Treatment; Triazoles

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

CANDIDA ALBICANS; CANDIDIASIS; CONFERENCE PAPER; CRITICAL ILLNESS; HOSPITAL INFECTION; HUMAN; INCIDENCE; MORTALITY; PATHOPHYSIOLOGY; PROPHYLAXIS; RISK FACTOR; SEPTIC SHOCK; CROSS INFECTION; REVIEW;

ANTIFUNGAL AGENTS; CANDIDIASIS; CRITICAL ILLNESS; CROSS INFECTION; HUMANS; INCIDENCE;

EID: 0034699848     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (122)

1. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals
2. Candida colonization and subsequent infections in critically ill surgical patients
3. Fungemia in a cancer hospital: Changing frequency, earlier onset, and results of therapy
4. Fungal infections in cancer patients: An international autopsy survey
5. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System
6. Clinical significance of Candida isolated from peritoneum in surgical patients
7. Fungal infections and their management
8. The intensive care unit
9. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
10. Epidemiology of Candidemia - A nationwide survey in Israel
11. National epidemiology of mycoses survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units
12. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study
13. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System
14. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of factors influencing outcome
15. Emergence of a new opportunistic pathogen, Candida lusitaniae
16. An outbreak of Candida parapsilosis bloodstream infections in patients receiving parenteral nutrition
17. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
18. The epidemiology of hematogenous candidiasis by different Candida species
19. Hospital-acquired candidemia. The attributable mortality and excess length of stay
20. Etiologic organisms as independent predictors of death and morbidity associated with bloodstream infections
21. Risk factors for nosocomial candidemia: A case-control study in adults without leukemia
22. Microbiological factors influencing the outcome of nosocomial bloodstream infections. A six-year validated, population-based model
23. Association of secondary and polymicrobial nosocomial bloodstream infections with higher mortality
24. Gastrointestinal colonization with yeast species and Candida septicemia in very low birth weight infants
25. Effect of various antibiotics on gastrointestinal colonization aud dissemination by Candida albicans
26. Evidence of nosocomial spread of Candida albicans causing bloodstream infection in a neonatal intensive care unit
27. Investigation of a cluster of systemic Candida albicans infections in a neonatal intensive care unit
28. Outbreak of systemic Candida albicans in intensive care unit caused by cross infection
29. Single-source outbreak of Candida tropicalis complicating coronary bypass surgery
30. Hospital outbreaks with yeasts
31. A study of a hospital cluster of systemic candidosis using DNA typing methods
32. Risk factors for hospital-acquired candidemia. A matched case-control study
33. Nosocomial infection and fatality in medical surgical intensive care unit patients
34. Number of comorbidities as a predictor of nosocomial infection acquisition
35. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care
36. Natural history of bloodstream infections in a burn patient population: The importance of candidemia
37. Risk factors for candidemia in patients with acute lymphocytic leukemia
38. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe
39. The role of Candida in intraperitoneal infections
40. Candida colonization and systemic infection in neutropenic patients. A retrospective study
41. Early Candida isolations in febrile patients after abdominal surgery
42. International conference for the development of a consensus on the management and prevention of severe candidal infections
43. Fungal sepsis: Multisite colonization versus fungemia
44. Nosocomial candidemia: Risk factors and attributable mortality
45. Predictors of adverse outcome in cancer patients with candidemia
46. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
47. Primary Candida pneumonia. Experience at a large cancer center and review of the literature
48. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality
49. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American College of Chest Physicians/Society of Critical Care Medicine
50. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study
51. Fungal infections in the critically ill
52. The role of Candida spp isolated from bronchoscopic samples in nonneutropenic patients
53. International conference for the development of a consensus on the management and prevention of severe candidal infections
54. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study
55. Peritonitis into the 1990s: Changing pathogens and changing strategies in the critically ill
56. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans
57. Clinicians' reaction to positive urine culture for Candida organisms
58. Yeast in the urine: Solutions for a budding problem
59. The risk of positive cultures for Candida in the critically ill patient
60. High-dose fluconazole therapy in patients with severe fungal infections
61. Candiduria: A randomized, doubleblind study of treatment with fluconazole and placebo
62. Candida infections in the ICU
63. Laboratory diagnosis of invasive candidiasis
64. The use of molecular techniques for epidemiologic typing of Candida species
65. Use of monoclonal antibody in diagnosis of candidiasis caused by Candida albicans: Detection of circulating aspartyl proteinase antigen
66. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: Useful combined test for diagnosis of systemic candidiasis
67. Detection and identification of fungal pathogens in blood by using molecular probes
68. Fungal infection - Approach to the surgical patient at risk for candidiasis
69. When to start antifungal therapy in the nonneutropenic critically ill?
70. Management of deep Candida infection in surgical and intensive care unit patients
71. Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii
72. Candida lusitaniae: Frequency of recovery, colonization, infection, and amphotericin B resistance
73. Current strategies in the treatment of invasive Aspergillus infections in immunocompromised patients
74. Antifungal agents. Part I. Amphotericin B preparations and flucytosine
75. Randomized, prospective comparison of amphotericin B-deoxycholate infused over 4 or 24 hours
76. Treatment of opportunistic fungal infections
77. Oral azole drugs as systemic antifungal therapy
78. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group
79. Current strategies in the treatment of invasive Aspergillus infections in immunocompromised patients
80. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B
81. Emulsion of amphotericin B in intralipid 20%: In vitro efficacy
82. Flucytosine
83. Treatment of candidemia in critically ill surgical patients with intravenous fluconazole
84. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature
85. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study
86. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia
87. Treatment of Candida albicans fungaemia with fluconazole
88. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy
89. Hepatosplenic candidiasis: Successful treatment with fluconazole
90. Candidemia in children with central venous catheters: Role of catheter removal and amphotericin B therapy
91. Vascular catheter-associated fungemia in patients with cancer: Analysis of 155 episodes
92. Therapeutic approaches in patients with candidemia
93. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group
94. Azole antifungal agents: Emerging and inherent resistance
95. Resistance of Candida species to fluconazole
96. Fluconazole disk diffusion procedure for determining susceptibility of Candida species
97. Development of interpretative breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards
98. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
99. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
100. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group
101. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients
102. Prevention of severe Candida spp infections in nonneutropenic, high-risk critically ill patients
103. Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species
104. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients
105. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe)
106. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in north America and Latin America, 1997-1998
107. Hand-washing and nosocomial infections
108. No time for handwashing? Handwashing versus alcoholic rub: Can we afford 100% compliance?
109. Compliance with handwashing in a teaching hospital
110. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
111. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group
112. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
113. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation
114. Intra-abdominal fungal infections after pancreatic transplantation: Incidence, treatment, and outcome
115. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia lung transplant group
116. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group
117. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo- controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS
118. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group
119. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group
120. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients
121. Hepatosplenic candidiasis in patients with acute leukemia: Incidence and prognostic implications
122. A double-blind placebo-controlled trial of prophylactic fluconazole to prevent Candida infections in critically ill surgical patients